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Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) is a major form of chronic liver disease in the
general population in relation to its high prevalence among overweight/obese individuals
and patients with diabetes type II or metabolic syndrome. NAFLD can progress to steatohe-
patitis (NASH), fibrosis and cirrhosis and end-stage of liver disease but mechanisms
involved are still incompletely characterized. Within the mechanisms proposed to mediate
the progression of NAFLD, lipotoxicity is believed to play a major role. In the present study
we provide data suggesting that microvesicles (MVs) released by fat-laden cells undergoing
lipotoxicity can activate NLRP3 inflammasome following internalization by either cells of
hepatocellular origin or macrophages. Inflammasome activation involves NF-kB-mediated
up-regulation of NLRP3, pro-caspase-1 and pro-Interleukin-1, then inflammasome complex
formation and Caspase-1 activation leading finally to an increased release of IL-1β. Since
the release of MVs from lipotoxic cells and the activation of NLRP3 inflammasome have
been reported to occur in vivo in either clinical or experimental NASH, these data suggest a
novel rational link between lipotoxicity and increased inflammatory response.
Introduction
Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged in recent years as a major form of
chronic liver disease affecting both children and adults worldwide, with a prevalence ranging
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from 3–15% in the general population and up to 70% among overweight individuals [1–5].
Epidemiological data indicate that 20–30% of NAFLD patients, particularly obese and/or dia-
betic type II and/or those affected by metabolic syndrome, can develop Non-Alcoholic Steato-
Hepatitis (NASH) and fibrosis and eventually progress to cirrhosis and end-stage liver disease
[1–9]. In the natural history of the disease, an increase in hepatic lipid deposit (i.e., fatty liver
or steatosis) is considered a required early event and prerequisite, potentially benign, for the
development of NASH [1–9]. Along these lines, a large body of literature data supports the
notion that upon lipid accumulation within parenchymal cells certain lipids, in particular satu-
rated fatty acids, can exert cyto-toxic effects also known as lipotoxicity, resulting in hepatocyte
damage and in triggering inflammatory responses [10–12].
In this scenario, recent data suggest that fat-laden hepatocytes undergoing lipotoxicity may
release extracellular vesicles (EVs). EVs are an heterogeneous family of small membrane vesi-
cles released by dying or activated cells that includes exosomes (30–100 nm in diameter),
released by exocytosis and microparticles or microvesicles (MVs, 100–1000 nm in diameter)
[13,14]. MVs, in particular, are small vesicles surrounded by a phospholipid bilayer, generated
and released through a controlled budding/blebbing of the plasma membrane [13]. These
MVs can act in an autocrine/paracrine manner carrying to surrounding cells several mole-
cules, including surface receptors, membrane, cytosolic or even nuclear proteins, lipids and
RNAs (mRNAs and microRNAs) [14–16]. These MVs, can either remain in the tissue of origin
or get into the blood circulation, delivering “molecular information” to target cells by either
interacting with surface receptors and/or following internalization [17–18].
Concerning liver parenchymal cells, previous studies have established that both primary
hepatocytes and immortalized cells of hepatocellular origin can release both exosomes and
MVs [19–22]. Furthermore, increased circulating levels of MVs are associated with liver injury
in either “in vivo” models of chronic liver diseases or human blood samples from patients
with NAFLD and alcohol or chronic hepatitis C related cirrhosis [19, 22–26]. With regard to
NAFLD progression, we have reported that MVs are released by hepatocytes undergoing lipo-
toxicity in a caspase-3 dependent manner and act as pro-angiogenic and profibrogenic stimuli
promoting endothelial and hepatic stellate cells activation [22,23]. In the same experimental
setting a recent study has also shown that MVs released by fat-laden hepatocytes or HuH7 cells
may act as pro-inflammatory stimuli on macrophages through signals operated by tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL), expressed on the surface of these
MVs [27]. Along these lines, one of the most recently identified contributor to the cross talk
between hepatocytes and inflammatory macrophages is represented by the multiprotein plat-
form complex nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3)
inflammasome, whose activation has been suggested to play a crucial role in the progression of
NAFLD [28]. In particular, the transition from NAFLD to NASH associates with NLRP3-in-
flammasome activation and an increased expression of inflammasome-related components,
including apoptosis-associated speck-like protein containing a carboxy-terminal CARD
(ASC), caspase-1 (CASP-1) and pannexin [28–32]. In addition, inflammasome activation
involves not only liver innate immunity cells but also parenchymal cells [29,31,32], with stud-
ies indicating that saturated fatty acids can specifically activate the inflammasome complex in
hepatocytes inducing IL-1β expression and release [29,32]. However, no study has so far inves-
tigated whether MVs released from fat-laden hepatocytes may promote NLRP3-inflamma-
some activation [28].
In the present study we provide for the first time evidence that MVs released by fat-laden
cells can directly up-regulate NLRP3 inflammasome in both hepatocytes and macrophages,
resulting in a significant increase in IL-1β release.
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Materials and methods
Materials
Enhanced chemiluminescence (ECL) reagents, nitrocellulose membranes (Hybond-C extra),
and secondary Cy3-conjugated antibodies were from Amersham Pharmacia Biotech Inc. (Pis-
cataway, NJ, USA). Polyclonal antibodies against NF-kB p65 (#8242), IKKβ (#2370) and p-
IKK α/β (#2697) or monoclonal antibodies against IKB (#4814) and p-IKB (#9246) were from
Cell Signalling Technologies (Danvers, Massachusetts); polyclonal antibodies against IL-1β
(sc-7884), caspase p10 (sc-515) and LaminA (sc-20680) were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA); monoclonal antibodies against NLRP3 were from Abcam (Cambridge,
UK, code ab109314) or from Adipogen (Adipogen AG, Liestal, Switzerland, code AG-20B-
0014-C100). Monoclonal antibodies for α-tubulin and β-actin and all other reagents of analyti-
cal grade were from Sigma Chemical Co (Sigma Aldrich Spa, Milan, Italy). HiPerfect Transfec-
tion Reagent was from Qiagen (QIAGEN S.r.l., Milan, Italy). ELISA kit for human IL-1β was
from Abcam (Cambridge, UK, code ab100562).
Animal experiments
Eight-week old male C57BL/6 mice were purchased from Charles River Laboratories (Charles
River UK Ltd., Margate, UK) and fed for 4 or 8 weeks with either methionine- and choline-defi-
cient (MCD) diet or related control diet sufficient in methionine and choline (MCS) (Laboratorio
Dottori Piccioni, Gessate, Italy) as previously described [33]. Experiments were approved by the
Italian Ministry of Health and by the university commission or animal care following the criteria
of the Italian National Research Council. The experimental MCD and MCS diets were also
administered to C57BL/6 caspase 3 knockout (Casp3−/−) mice and related wild type littermates
up to 6 weeks exactly as previously described [22]. The latter genetically manipulated mice and
their littermates were treated in compliance with the Guide for the Care and Use of Laboratory
Animals (National Academy of Science,Washington, DC), and animal procedures were approved
by the University of California, San Diego, Institutional Animal Care and Use Committee.
Cell lines and culture conditions
HepG2 and THP-1 cells (American Type Culture Collection, USA) were maintained in Dul-
becco’s modified Eagle’s medium or RPMI 1640 respectively supplemented with 10% fetal-
bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 25 μg/ml amphotericin-B. To
evaluate the role of LPS, palmitic acid (PA, 0,25mM) or MVs, HepG2 cells were seeded in nor-
moxic conditions to obtain the desired sub-confluence level (65–70%) and then incubated in
experimental conditions (up to 48h hours). THP-1 cells were seeded 7x105 in 35 mm petri
dishes and differentiated for 48 hrs with phorbol 12-myristate 13-acetate (PMA, 50nM); after
24 hrs of incubation with fresh medium THP-1 cells were properly stimulated. mRNA, cellular
extracts and the corresponding medium were tested for inflammasome components (NLRP-3
and caspase-1) and related cytokine (IL-1β). In some experiments HepG2 cells were trans-
fected with specific siRNA for caspase-3 or NLRP3 and non-silencing siRNA (scramble, SC).
MVs isolation and purification and other related methodological issues
The procedures adopted in this study to isolate, purify, quantify and characterize MVs obtained
from fat-laden HepG2 have been extensively described in previous studies [22,23,26]. Briefly, for
MVs isolation HepG2 cells were seeded onto a 100-mm dish and cultured until they reached 80
to 85% confluency. Cells were then incubated with 0.25 mM palmitic acid (PA) in serum-free
DMEM, supplemented with 1.1% penicillin and streptomycin and 1% endotoxin-free bovine
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serum albumin (BSA) for up to 24 hours. The uptake of FFAs from hepatocytes was evaluated with
an Oil Red-O staining according to the manufacturer’s instruction (see later). Control cells were
incubated with the same serum-free medium supplemented with the vehicle used to dissolve PA.
MVs were then isolated by differential centrifugation and characterized essentially as previ-
ously described [22,23,26]. The isolation procedure involved the following steps: i) collected
media were centrifuged at 3000 g for 15 min to remove cell debris and aggregates; ii) the super-
natant from last centrifugation were then transferred to new tubes and ultra-centrifuged at
100,000 g for 90 minutes at 10˚ C; iii) the supernatants collected from the latter step were used
as MVs-free control whereas the pelleted MVs fraction were gently re-suspended into 500 μl of
PBS for flow cytometry or in 500 μl of serum-free DMEM medium and used for subsequent in
vitro studies. To trace hepatocyte-derived MVs in flow cytometry and confocal analysis, the
PKH26 fluorescent dye (Sigma-Aldrich) was used, according to the manufacturer’s instruc-
tions and as previously described (22).
A complete characterization of MVs, including size, composition and distribution, was per-
formed by dynamic light scattering, TEM (see here S1A Fig) and FACS as reported previously
[22].
MVs were quantified either by the bicinchoninic acid (BCA) protein assay [22] or (see S1B
Fig) by flow cytometry using MVs resuspended in PBS and the Calcein AM (BD Biosciences,
San Jose, CA, USA)—based procedure previously described [26]. The preparations of MVs
employed in the present study were also tested for presence of NLRP3 and IL-1β protein levels
and, as shown in S1C Fig, we could not find any trace of such proteins in pelleted MVs. In addi-
tion, no trace of mRNA levels for NLRP3 or IL-1β could be detected in MVs (data not shown).
Quantitative real-time PCR (Q-PCR)
RNA extraction, complementary DNA synthesis, quantitative real-time PCR (Q-PCR) reactions
were performed as previously described [34]. Human or murine NLRP3, IL1β and CASP-1
mRNA levels were measured by Q-PCR, using the SYBR1 green method as described [34]. The
amplification mix was prepared using Roche LightCycler FastStart DNA MasterPLUS SYBR
Green I kit following manufacturer’s instructions and real-time PCR was performed using Light-
Cycler instrument. Oligonucleotide sequence of primers used for RT-PCR were: sense, 5’-TGA
AAGCTCTCCACCTCCAG-3’, reverse 5’-CACGCAGGACAGGTACAGAT-3’ (for human IL-
1β); sense, 5’-AAGGAAGTGGACTGCGAGAA-3’, reverse 5’-CCCTCGAATTTGCCATA-3’
(for human NLRP3); sense, 5’-GCTTTCTGCTCTTCCACACC-3’, reverse 5’-CATCTGGCTG
CTCAAATGAA-3’ (for human CASP-1); sense, 5’-TGCTCTTCACTGCTATCAAGCCCT-3',
reverse 5'-ACAAGCCTTTGCTCCAGACCCTAT-30 (for murine NLRP3); sense, 5'-GGAGAAC
CAAGCAACGACAAAATA-3', reverse 5'-TGGGGAACTCTGCAGACTCAAAC-30 (for murine
IL-1β); sense, 50-TCCGCGGTTGAATCCTTTTCAGA-3', reverse 50-ACCACAATTGCTGTGTG
TGCGCA-3 (for murine caspase-1); sense, 5'-TGGCCCAGACCCTCACACTCAG-3', reverse,
5'-ACCCATCGGCTGGCACCACT-3' (for murine TNF-α). Gliceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as internal reference and co-amplified with target samples using
identical Q-PCR conditions. Samples were run in triplicate and mRNA expression was generated
for each sample. Specificity of the amplified PCR products was determined by melting curve
analysis and confirmed by agarose gel electrophoresis.
Caspase-3 and NLRP3 silencing by small RNA interference
RNA interference experiments to knockdown caspase-3 or NLRP3 expression in HepG2 cells
were performed using siRNA duplex (Qiagen Italia, Milano, Italy) as previously described
[35]. The following target sequences were used:
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Fig 1. In vivo time-dependent analyses of inflammasome components, inflammatory cytokines and necrosis in MCD fed
mice. “In vivo” analysis by quantitative real-time PCR (qPCR) of transcripts of inflammasome components (NLRP3 and CASP-1
A, C) and related cytokine (IL-1β, B) as well as of TNF-α (E) in WT mice fed with MCS diet or MCD diet for 4d, 2wks, 4wks and
8wks. D. Analysis of serum ALT in WT mice fed with MCS diet or MCD diet for 2wks, 4wks and 8 wks. Data in graphs are
expressed as means ± SEM (n = 6 mice for any experimental group); p values are indicated and referred to mice fed the MCS
control diet.
doi:10.1371/journal.pone.0172575.g001
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Fig 2. Immunohistochemistry analysis for NLRP3 and F4/80. A,B. Immunohistochemistry analysis for NLRP3 on liver
specimens from WT mice fed with MCS diet or MCD diet for 2wks, 4wks and 8wks (A) as well as WT mice and Casp 3-/-
knockout mice fed for 6wks (B). C. Image analysis quantification for NLRP3 staining (Fig 2B) as evaluated with Imagej software
Microvesicles from cells undergoing lipotoxicity activate NLRP3 inflammasome
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NLRP3: 5’-AAGGTGTTGGAATTAGACAAC-3’;
CASP3: 5’-CTGAGATGGGTTTATGTATAA-3’.
The siRNAs and related non-silencing controls were transfected in HepG2 cells with
HiPerfect Transfection reagent (Qiagen Italia, Milano, Italy) according to manufacturer’s
instructions up to 48hrs (CASP3) or 72hrs (NLRP3). Transfected cells in fresh medium
were then exposed to the desired experimental conditions and then harvested for sample
preparation.
Western blot analysis
Total cell lysates and nuclear vs cytosolic extracts, obtained as described, [35, 36] as well as
MVs preparations (the latter by resuspending pelleted MVs directly in RIPA buffer) were sub-
jected to sodium dodecyl sulfate-polyacrylamide gel-electrophoresis on 12%, 10% or 7.5%
acrylamide gels, incubated with desired primary antibodies, then with peroxidase-conjugated
anti-mouse or anti-rabbit immunoglobulins in Tris-buffered saline-Tween containing 2%
(w/v) non-fat dry milk and finally developed with the ECL reagents according to manufactur-
er’s instructions. Sample loading was evaluated by reblotting the same membrane with anti-
bodies raised against β-actin or α-tubulin or, for nuclear extracts, Lamin A.
Immunohistochemistry, immunofluorescence and histo-morphometric
analysis
Paraffin liver sections of specimens derived from patients with NAFLD/NASH-related ad-
vanced fibrosis or derived from either wild type C57BL/6 mice or caspase 3 -/- mice fed MCD
diet or related control diet (MCS) as well as from the liver of NLRP3 +/- mice, were analyzed
as previously described [33,34]. The use of human material conforms to the ethical guidelines
of the 1975 Declaration of Helsinki and was approved for this study by the University of
Torino Bioethical Committee. Immunostaining procedure were performed, according to
established procedures previously described in detail [33,37], on paraffin sections (2 μm thick),
mounted on poly-L-lysine coated slides, that were incubated with the antibodies against
NLRP3 (Abcam, Cambridge, UK, dilution 1:100, or from Adipogen AG, Liestal, Switzerland,
dilution 1:100) and murine F4/80 (Affimetrix, Cleveland, OH, USA, dilution 1:1000) or
human CD68 (Bio-Rad; Segrate—MI, dilution 1:40). After blocking endogenous peroxidase
activity with 3% hydrogen peroxide and performing microwave antigen retrieval, primary
antibodies were labeled by using EnVision, HRP-labeled System (DAKO) and visualized by
3’-diaminobenzidine substrate. For negative controls the primary antibodies were replaced by
isotype- and concentrations-matched irrelevant antibody [33,37]. Quantification of NLRP3
positive immunostaining in murine liver was also performed by histo-morphometric analysis
using a digital camera and a bright field microscope to collect images that were then analyzed
by employing the ImageJ software.
Indirect immunofluorescence and confocal microscopy analysis was performed on cultured
cells as previously described [35,36] by employing a primary rabbit polyclonal antibody raised
against NF-kB p65 (Cell Signalling Technology, Danvers, MA, USA; diluted 1:400). Nuclei
were stained using 4,6-diamino-2-phenylindole (DAPI, blue fluorescence).
in liver sections from WT or caspase 3 -/- mice fed a MCD diet for 6 weeks. D,E. Immunohistochemistry analysis for F4/80 on
liver specimens from WT mice fed with MCS diet or MCD diet for 2wks, 4wks and 8wks (D) as well as WT mice and Casp 3-/-
knockout mice fed for 6wks (E). F. Immunohistochemistry analysis for NLRP3 and CD68 on liver specimens from human
NAFLD/NASH-related advanced fibrosis (F3 and F4). Original magnification as indicated.
doi:10.1371/journal.pone.0172575.g002
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Fig 3. In vitro experimental model of lipotoxicity. A. Red Oil-O staining in control HepG2 cells, HepG2 cells treated with BSA
1% or HepG2 cells exposed to palmitic acid 0.25mM in BSA 1% (BSA + PA) for 24hrs. B. Detection of Caspase-3/7 Activity in
HepG2 cells treated with BSA 1% or PA 0.25mM for indicated times, analyzed by using Apo-ONE Caspase-3/7 Homogeneous
Microvesicles from cells undergoing lipotoxicity activate NLRP3 inflammasome
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Internalization of MVs
Cultured cells, seeded in 6-well culture plates (105 cells/well) or on microscope slides, were
exposed for 1 hour (THP-1) or 3 hrs (HepG2) to PKH26 fluorescent dye -MVs released by
HepG2 treated with palmitic acid (0,25mM) as previously described [22]. Internalization of
MVs was evaluated by: a) flow cytometric analysis: cells were rapidly washed with PBS, col-
lected by trypsinization and re-suspended in PBS for analysis. Detection of PKH26 red fluores-
cent die-MVs (FL2) was performed on at least 5,000 cells per sample with a FACScan using
the CellQuest software (Becton-Dickinson, Milano, Italy); b) indirect immunofluorescence
and confocal microscopy analysis: nuclei (blue fluorescence) were stained using 4,6-diamino-
2-phenylindole (DAPI), MVs were stained with PKH26 fluorescent die (red fluorescence) and
cytoskeleton were marked with Alexa Fluor 488 phalloidin (high-affinity filamentous actin,
F-actin, green fluorescence) and slides were examined with an Olympus Fluoview 300 confocal
laser scanning microscope.
Red oil staining
HepG2 cells were seeded in 6-wells culture plates until reaching 80–85% of confluence and
incubated with 0.25 mM palmitic acid in serum-free DMEM, supplemented with 1.1% penicil-
lin and streptomycin and 1% endotoxin-free BSA, for up to 24 hours. Control cells were incu-
bated with the same serum-free medium supplemented with the vehicle used to dissolve the
FFAs. After treatment, cells were fixed with 4% of paraformaldehyde and the uptake of FFAs
from HepG2 cells was detected by staining cells for 30 minutes with Oil-Red-O 0,5% (Sigma-
Aldrich, St. Louis, MO, USA) diluted in isopropanol, according to the manufacturer’s instruc-
tion. Then, bright field microscope was employed to collect images.
Biochemical analysis
Plasma alanine aminotransferase (ALT) and liver triglycerides (TGs) were determined by
spectrometric kits supplied by Radim S.p.A. (Pomezia, Italy) and Sigma Diagnostics (Milano,
Italy), respectively. Release of IL-1β in culture medium was evaluated, according to the manu-
facturer’s instructions by commercial enzyme-linked immunosorbent assay (ELISA) kit sup-
plied by Abcam (Cambridge, UK).
Detection of caspase-3/7 activity in cell culture
Caspase-3/7 activity as a measure of apoptotic cell death was determined in HepG2 cells
exposed to palmitic acid (0,25 mM) for 24 hrs and following the manufacturer’s instructions
(Apo-ONE Caspase-3/7 Homogeneous Assay, (Promega, Madison, WL, USA). After the treat-
ment HepG2 cells were washed twice with PBS and a volume of 50 μL of homogeneous cas-
pase-3/7 reagent was added to each well. The plate was incubated for 1 h at room temperature.
After this time, fluorescence was measured in a fluorimeter at excitation 499 nm and emission
521 nm.
MTT assay
Viability of HepG2 cells was evaluated by the MTT colorimetric assay. HepG2 cells were seeded
1x104 in 96-wells plates for each wells and incubated with 0.25 mM palmitic acid in serum-free
Assay. C. Viability of HepG2 cells treated with BSA 1% or PA 0.25mM for indicated times, evaluated by MTT assay. D,E.
Analysis of internalization of MVs in HepG2 cells by (D) flow cytometry or by (E) confocal microscopy: nuclei (blue fluorescence),
MVs (red fluorescence) and cytoskeleton (F-actin, green fluorescence).
doi:10.1371/journal.pone.0172575.g003
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Fig 4. MVs activate NLRP3 inflammasome cascade. A, B. Quantitative real-time PCR (qPCR) analysis of inflammasome
components (NLRP3 and CASP-1) in HepG2 naïve cells treated with MVs up to 24 hrs. C. Western blot analysis of activation
of inflammasome pathway by evaluating NLRP3 protein levels as well as cleaved caspase-1 (p-10-CASP-1) and IL-1β in
total extracts obtained by HepG2 naïve cells exposed to MVs for indicated times. Equal loading was confirm by re-probing the
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DMEM, supplemented with 1.1% penicillin and streptomycin and 1% endotoxin-free BSA, for
up to 24 hours. Control cells were incubated with the same serum-free medium supplemented
with the vehicle used to dissolve the FFAs. After treatment, 30 μl of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5mg/ml in PBS solution) was added to each well
and incubated up to 2 hrs at 37˚. Then, 150 μl of DMSO was added to empty wells for 20 min-
utes at room temperature. After this time, fluorescence was measured in a ELISA plate reader at
absorbance of 540 nm.
Statistical analysis
For cell culture experiments data in bar graphs represent means ± SEM, and were obtained
from average data of at least three independent experiments. Luminograms and morphological
images are representative of at least three experiments with similar results. Statistical analysis
for these experiments was performed by Student’s t-test or ANOVA for analysis of variance
when appropriate (p< 0.05 was considered significant).
Results
The aim of the present study has been to investigate the possible role of MVs released from fat-
laden cells in promoting NLRP3 inflammasome activation in either parenchymal cells and
macrophages. According to recent literature data, inflammasome activation is fully detectable
in association with overt steatohepatitis in experimental murine models of progressive NASH
and such an activation involves liver innate immunity cells and hepatocytes [29,31,32]. In line
with these findings, our experiments using mice fed with a methionine/choline deficient
(MCD) diet showed that the transcript levels for NLRP3 and IL1β were significantly up-regu-
lated after 4 weeks of treatment (Fig 1A, Fig 1B) in parallel with an appreciable worsening of
lobular inflammation and parenchymal damage (Fig 1D, Fig 1E). No appreciable changes were
evident at earlier time points. Similar data were obtained by evaluating caspase 1 transcripts,
with the exception of a transient increase detected at 4 days (Fig 1C).
In line with these data, NLRP3 immunohistochemical analysis showed and appreciable
increase in mice fed the MCD diet for 4 weeks (Fig 2A). In these animals, NLPR3 up-regula-
tion paralleled with a progressive recruitment of hepatic macrophages as evidenced by F4/80
immunostaining (Fig 2D). This scenario is also consistent to what is occurring in liver speci-
mens from human NASH in which NLRP3 positivity was detectable at immunohistochemistry
in parenchymal cells and in CD68 positive macrophages (Fig 2F).
Since in a previous study some of us reported that MVs production associated with NASH
required caspase-3 activity and was appreciably decreased in caspase-3 knock out (caspase-3-/-)
mice fed with the MCD diet [22], here we evaluated whether the lack of MVs production in cas-
pase-3-/- animals might affect NLRP3 responses. As shown in Fig 2B, NLRP3 staining was appre-
ciably reduced in caspase-3-/- mice as compared to WT littermates, as also confirmed by histo-
morphometric analysis (Fig 2C). In a similar manner liver macrophage infiltration was signifi-
cantly lower in MCD-fed caspase-3-/- mice as compared to similarly treated WT animals (Fig 2E).
These data were confirmed by histo-morphometric analysis by employing a different anti-
body targeting NLRP3 either in NLRP3 +/- mice (S2A Fig) as well in either wild type and Cas-
pase 3 -/- mice fed 6 wks with MCD diet (S2B Fig).
same membrane with monoclonal antibody against the house-keeping β-actin. D. ELISA assay to evaluate IL-1β release (pg/
ml) in culture medium of HepG2 naïve cells exposed to MVs up to 16 hrs. Data in graphs are expressed as means ± SEM
(*p< 0.05 and ** p<0.01 vs related control HepG2 cells) of three independent experiments.
doi:10.1371/journal.pone.0172575.g004
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Fig 5. MVs up-regulate NF-KB pathway. A. Western blot analysis of activation of IKK and IKβ evaluated in
total extracts of HepG2 naïve cells exposed to MVs for indicating time. Equal loading was confirmed by re-
probing the same membrane with un-phosphorylated protein. B. Western blot analysis of NF-Kb/p65 protein
levels in cytosolic and nuclear extract obtained from HepG2 naïve cells exposed to MVs up to 16 hrs. Equal
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On the basis of these observations, we then designed experiments to directly investigate the
hypothesis that MVs released by fat-laden cells may affect synthesis and activity of NLRP3
inflammasome. In order to do so we employed a well established “in vitro” model to generate
MVs based on the exposure of hepatocytes or immortalized cells (HepG2 or HuH7) cells to
0.25 mM palmitic acid [22,27]. In the present study, in order to maintain reproducible condi-
tions in the different experiments, we employed human HepG2 cells.
As expected, the incubation of HepG2 cells with palmitic acid resulted in a significant intra-
cellular accumulation of lipids, as shown by Oil-Red-O staining (Fig 3A), as well as in a condi-
tions of progressive caspase–dependent lipoapoptosis, as evidenced by Caspase 3/7 and MTT
assays (Fig 3B, Fig 3C). The culture media was used to isolate MVs released by fat laden
HepG2-cells as previously described [22]. Protein content of the preparations of MVs in these
experiments gave mean routine values from control cells of 0.02–0.03 μg/μl vs values of 4.3–
4.6 μg/μl from cells exposed to PA for 24 hrs.
Interestingly, the addition to HepG2 cells of purified MVs conjugated with the fluorescent
dye PKH26 lead to an internalization (within 3 hours) of red fluorescent MVs as shown by
either flow cytometry analysis (Fig 3D) or by using confocal laser microscopy (Fig 3E).
We next analysed whether HepG2 cells exposure to MVs may modulate inflammasome
activation. Fig 4 shows that MVs addition to resting HepG2 cells was followed within 3 hours
by a significant up-regulation of the transcripts levels for NLRP3 (Fig 4A) and Caspase-1 (Fig
4B). When analysed in Western blots MVs-treated HepG2 cells also showed time-dependent
increase in NLRP3, pro-IL-1β and pro-caspase-1 proteins levels that were associated with an
early detection of active caspase-1 that was detected starting from 3 hrs and detectable until 48
hrs (Fig 4C). Conversely IL-1β protein levels were consistently enhanced at 16 hrs and thereaf-
ter (Fig 4C). ELISA assay analysis of IL-1β released in the culture media revealed that MVs
exposure resulted in a rather early, although limited, release of the cytokine at 3 and 6 hrs to
reach a significant level at 16 hrs (Fig 4D).
It is known that NLRP3 expression requires NF-kB phosphorylation and its nuclear translo-
cation [28]. To get more insights on the mechanisms responsible for inflammasome activation
by MVs we next analysed whether MVs may be able to modulate NF-kB pathway. In our hand,
HepG2 cells exposure to MVs was followed by a very early phosphorylation of both IkB kinase
(IKK) and of Ikβ (Fig 5A) as well as by an increase of p65 subunit in both the cytosolic and in
nuclear extracts (Fig 5B). Nuclear translocation of p65 was further confirmed by means of
indirect immunofluorescence (Fig 5C).
From the data showing that caspase-3 deficiency can prevent NLRP3 up-regulation in mice
fed the MCD diet, we next decided to deplete this enzyme by means of a specific siRNA.
According to previous reports [22], blocking caspase-3 in HepG2 cells before lipid loading
(Fig 6A) resulted in a decrease in the release of MVs that (as also documented by analysis of
protein content of MVs preparations from cells silenced or not for caspase 3, see Fig 6B) that
was reflected by a sharp reduction in MVs internalization in naïve HepG2 cells (Fig 6C) as
compared to cells exposed to non-silencing siRNA. Moreover, the relationships between MVs
and NF-kB pathway was further supported by the observation that the exposure of naïve
HepG2 cells to MVs from cells treated with caspase-3 siRNA resulted in a significant decrease
in p65 nuclear translocation as compared to cells receiving MVs from cells treated with the
non-silencing vector (Fig 6D). Accordingly, silencing of caspase-3 in the parental fat-laden
loading was confirmed by re-probing membrane with α-tubulin and Lamin-A (cytosolic and nuclear house-
keeping, respectively). C. Immunofluorescence analysis of NF-Kb/p65 nuclear translocation in control HepG2
cells or HepG2 cells exposed to MVs for 6hrs: nuclei (blue, DAPI staining), NF-Kb/p65 (green). Original
magnifications are indicated.
doi:10.1371/journal.pone.0172575.g005
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Fig 6. NLRP3 inflammasome activation is prevented by blocking the caspase 3 –dependent release of MVs. A. Western
blot analysis of caspase-3 in total extracts of HepG2 cells not transfected (C), transfected with non-silencing siRNA (NsC) or
specific siRNA for caspase-3 (siCASP3) and treated with palmitic acid 0,25mM for 24hrs. Equal loading was confirm by re-
probing the same membrane with monoclonal antibody against the house-keeping β-actin. B. Protein quantification of preparation
of MVs as obtained from control HepG2 cells (C), from HepG2 cells transfected with the non silencing RNA and then exposed to
PA (NsC) and HepG2 cells silenced for caspase 3 and then exposed to PA (siCASP3). Data are expressed as μg/μl and as
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cells led to a decrease in the protein levels of the inflammasome components (Fig 6E) as com-
pared to fat-laden cells receiving the non-silencing control vector.
In order to establish whether the MVs-induced release of IL-1β was directly dependent on
NLRP3 inflammasome, HepG2 cells were depleted of NLRP3 using a specific siRNA before
exposure to MVs for 16 or 24 hrs. In control arm cells were exposed to a non-silencing vector.
HepG2 cells silenced for NLRP3 responded to MVs by a sharp decrease in NLRP3 transcript
(Fig 7A) as well as by low protein levels of activated caspase-1 (Fig 7B) and IL-1β (Fig 7C). In
addition, NLRP3 silencing in HepG2 cells also resulted (Fig 7D) in a reduction of transcript
levels for IL-1β (i.e., pro-IL-1β in this case).
Finally, additional experiments were performed to verify whether MVs may be able also to
promote inflammasome activation in macrophages. To this aim, we exposed macrophage dif-
ferentiated from human THP-1 cells to MVs obtained from fat-laden HepG2 cells. In differen-
tiated THP1 cells we observed a rapid (as early as after 1 hr) internalization of MVs marked
with the fluorescent dye PKH26 (Fig 8A, Fig 8B) as well as an increase in transcript levels of
NLRP3, Caspase-1 and IL-1β (Fig 8C–8E) accompanied by a time-dependent increase in IL-1β
release in the extracellular medium (Fig 8F).
Discussion
Hepatocyte injury due to lipotoxicity and inflammatory infiltration by cells of innate immu-
nity, mainly activated macrophages, are two well recognized pathological hallmarks of NASH
[10–12,38]. In this scenario, multiple hits involving oxidative stress, endotoxemia, cytokines
and gut microbiota have been suggested to play a role in favouring NAFLD progression to
NASH [10–12,38–40]. In recent years different reports have provided evidence that during
NAFLD progression hepatocyte injury induced by lipotoxicity may affect, and somehow drive,
the response of surrounding cells through the release of hepatocyte-derived MVs. At present,
MVs released by lipotoxic hepatocytes have been proposed to up-regulate angiogenic and pro-
fibrogenic responses in endothelial cells [19,22] and hepatic stellate cells [23], respectively.
Moreover, lipotoxicity-mediated MVs release has been recently shown to initiate a CHOP/
DR5/caspase 8/caspase-3 signalling cascade leading to the release of MVs expressing on their
surface TRAIL as molecule able to trigger a pro-inflammatory and NF-kB–dependent response
in macrophages [27], thus acting act as “messengers” between injured hepatocytes and macro-
phages [27,41].
In the present study we provide novel evidence suggesting that MVs released by cells under-
going lipotoxicity may actively contribute to pro-inflammatory responses by activating in a
paracrine way NLRP3 inflammasome in either parenchymal cells and macrophages with a
mechanism that involves MVs internalization by “target” cells. This is in agreement with
previous data showing that endocytosis is required for the triggering of MVs responses in
mean ± SD being (n = 12 for any condition). C. Flow cytometric analysis of internalization of PKH26-fluorescent die-MVs in HepG2
naïve cells. Color legend: i) black trace is related to HepG2 naïve cells treated with ultracentrifugated solution (also marked with
PKH26-fluorescent die) derived from cells just exposed to BSA (used as control), ii) pink trace is related to HepG2 naïve cells
treated with MVs derived from HepG2 cells transfected with non-silencing treated with palmitic acid 0,25mM for 24hrs; iii) green
trace is related to HepG2 naïve cells treated with MVs derived from HepG2 cells transfected with specific siRNA for caspase-3
and treated with palmitic acid 0,25mM for 24hrs. D. Western blot analysis of NF-Kb/p65 protein levels in cytosolic and nuclear
extract obtained from HepG2 naïve cells exposed or not (C) to MVs derived from HepG2 cells transfected with non-silencing
siRNA (NsC) or specific siRNA for caspase-3 (siCASP3) and treated with palmitic acid 0,25mM for 24hrs. Equal loading was
confirmed by re-probing membrane with α-tubulin and Lamin-A (cytosolic and nuclear house-keeping, respectively). E. Western
blot analysis of NLRP3 protein levels as well as of cleaved caspase-1 (p-10-CASP-1) and IL-1β in total extracts obtained by
HepG2 naïve cells exposed or not (C) to MVs derived from HepG2 cells transfected with non-silencing siRNA (NsC) or specific
siRNA for caspase-3 (siCASP3) and treated with palmitic acid 0,25mM for 24hrs. LPS 1mg/ml was used as positive control. Equal
loading was confirmed by re-probing membrane with β-actin.
doi:10.1371/journal.pone.0172575.g006
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Fig 7. Silencing of NLRP3 in target cells prevents MVs-dependent inflammasome activation. A. Quantitative
real-time PCR (qPCR) of NLRP3 mRNA in HepG2 cells transfected for 72hrs with non-silencing siRNA (NsC) or
specific siRNA for NLRP3 (siNLRP3) and exposed or not to MVs derived from HepG2 cells treated with PA 0.25mM for
24hrs. LPS 1mg/ml was used as positive control. B. Quantitative real-time PCR (qPCR) of IL-1βmRNA in HepG2 cells
not transfected (C) and transfected for 72hrs with non-silencing siRNA (NsC) or specific siRNA for NLRP3 (siNLRP3)
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endothelial and hepatic stellate cells [22,23]. The inflammasome stimulation results in caspase-
1 activation and a sustained release of IL-1β, an event that can support the lobular inflamma-
tion in NASH and contributes to the maintenance of insulin resistance [42–47].
It is well known that the inflammasome represents a multimeric protein complex which
senses several stimuli related to pathogen and damage-associated molecular patterns in tissues
undergoing infections, cell damage or metabolic imbalances [28,48,49]. The formation of the
inflammasome complex leads to the activation of caspase-1, which in turn proteolytically
cleaves the precursors of pro-inflammatory cytokines IL-1β and IL-18. Inflammasome
responses can also cause pyroptosis, a peculiar and rapid pro-inflammatory form of cell death
relevant in the so-called “sterile inflammation” which is known to occur also in NASH [49].
Along these lines, a recent study using mice expressing a constitutively active form of NLRP3
under the control of the endogenous NLPR3 promoter, has shown that increased NLRP3 activ-
ity results in extensive liver inflammation, hepatocyte pyroptosis, and liver fibrosis [30].
Indeed, activation of NLRP3 inflammasome in both hepatocytes and macrophages has been
detected only when NAFLD had advanced to NASH [28–33,50], a scenario that seems to be
confirmed by this study showing that NLRP3 protein is overexpressed in liver biopsies from
NASH patients. Furthermore, in MCD model of NASH hepatic NLRP3 and IL-1β transcript
levels are both increased only in severe steatohepatitis.
To characterize the mechanisms involved in MVs—induced activation of NLRP3 inflam-
masome we used a well characterized “in vitro” model of MVs release by fat-laden cells. This
model has been used by different laboratories in recent years [22,23,27] and is based on the
exposure of HepG2 cells to palmitic acid resulting in rapid intracellular lipid accumulation
that leads to the induction of caspase 3 –dependent lipoapoptosis and the release of MVs. The
capacity of MVs released by cells undergoing lipotoxicity to activate NLRP3 inflammasome is
supported by data indicating that activation is prevented by either blocking MVs production
by silencing caspase 3 in lipotoxic cells before exposure to palmitate or by the silencing NLRP3
target cells before exposure to MVs. Furthermore, MVs promote target cells release of IL-1β in
the extracellular medium. Such a release is evident in both HepG2 cells and macrophages 16
hrs after the addition of MVs, but already detectable, although at lower levels, at earlier time
points. The analysis of the events triggered by MVs suggests that they induce an early tran-
scription of NLRP3 and pro-IL-1β, likely through NF-kB–dependent signals as recently
described by Hirsova et al. [27]. However, protein analysis shows that that NLRP3 and pro-cas-
pase 1 are already present in resting cells and that their apparent levels increase not before 6
hrs of exposure to MVs. Of interest, the levels of active caspase 1 that is responsible for the
cleavage of pro-IL-1β start to increase already 1 hr after exposure to MVs. This suggests that
MVs internalization may lead to the assembly and activation of NLRP3 inflammasome even
before an increase in NLRP3 and pro-caspase 1 protein levels. This interpretation is in agree-
ment with literature data stating that NLRP3 canonical inflammasome activation can occur as
a two-step process, in which a first signal up-regulates NLRP3 expression through NFκB-
dependent pathways [51], while a second signal leads to multimeric protein complex assembly
and activation through distinct pathways [52–54], that involve the interaction between the
danger signal(s) and the NACHT domain of NLRP3. Although in the present study we have
and exposed or not for 3hrs to MVs derived from HepG2 cells treated with PA 0.25mM for 24hrs. Data in graphs are
expressed as means ± SEM (*p< 0.05 and ** p<0.01 vs related control HepG2 cells; # p<0.05 vs NsC+MVs) of three
independent experiments. C,D. Western blot analysis of NLRP3 protein levels as well as of cleaved caspase-1 (p-
10-CASP-1) and IL-1β in total extracts obtained by HepG2 cells transfected for 72hrs with non-silencing siRNA (NsC)
or specific siRNA for NLRP3 (siNLRP3) and exposed for indicating time to MVs derived from HepG2 cells treated with
PA 0.25mM for 24hrs. Equal loading was confirmed by re-probing membrane with β-actin.
doi:10.1371/journal.pone.0172575.g007
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Fig 8. MVs activate NLRP3 inflammasome in THP-1 differentiate macrophages. A,B. Analysis of internalization of MVs in
THP-1 cells by confocal microscope (3hrs): nuclei (blue fluorescence), MVs (red fluorescence) and cytoskeleton (F-actin, green
fluorescence) (A) or by flow cytometry (1 hr, B). C-E. Quantitative real-time PCR (qPCR) of NLRP3, caspase-1 and IL-1β
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not yet characterized the precise nature of signal(s) leading to MVs-mediate assembly/activa-
tion of inflammasome, the overall message is of potential relevance and further supports the
concept that MVs released by damaged cells undergoing lipotoxicity can have a role in sustain-
ing hepatic inflammation in NASH along with previously shown fibrogenesis and angiogene-
sis. Further experimental studies are needed in order to fully clarify and detail the reported
relationships between the release of MVs from fat laden hepatocytes and surrounding cells in
the scenario of NAFLD/NASH chronically injured microenvironment.
Supporting information
S1 Fig. Characterization of microvesicles (MVs) obtained from fat-laden HepG2 cells. (A).
Representative TEM micrograph of HepG2-derived MVs released after 24 hrs of 0.25 mM pal-
mitic acid (PA) treatment. Scale bar 200 nm. (B) Flow cytometry analysis (Whisker plot) of
Calcein+ MVs per mL of media isolated from fat-laden HepG2 cells at the end of 24 hrs expo-
sure to PA. Values represent mean ± SD of 6 different MVs preparations. P< 0.05. (C). West-
ern blot analysis of NLRP3 and IL-1β in the following experimental condition: 1: total extract
from MVs release from HepG2 cells treated for 24hrs with BSA (C-); 2: total extract from MVs
release from HepG2 cells treated for 24hrs with PA 25mM; 3:total extract from control HepG2
cells; 4: total extract from HepG2 cells treated with LPS 1μg/μl for 1 hr; 5: total extract from
HepG2 cells treated with PA 25mM for 24hrs. Equal loading was evaluated by re-probing the
same membrane with the monoclonal antibody targeting β-actin. Red ponceau images were
also included to show protein loading.
(TIF)
S2 Fig. Immunohistochemistry analysis for NLRP3 on liver specimens from NLRP3 hemizy-
gous +/-mice (A) as well as WT mice or Casp 3-/- knockout mice fed for 6wks with MCD diet
(B). Original magnification as indicated. Right panels represent histomorphometric analysis
(ImageJ program) that has been performed on n = 4 liver sections obtained from three differ-
ent animals for each condition indicated in panels A and B in order to evaluate positive stain-
ing for NLRP3.
(TIF)
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